Maternal RSV Vaccine Approved by FDA
27/10/2023
Aotearoa Clinical Trials is proud to have been part of the MATISSE Trial. ABRYSVO™, Pfizer’s bivalent RSV preF vaccine for the prevention of Lower Respiratory Tract Disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age was approved by the FDA on 21st August 2023.
Read more